As we know, besides LAC, other procoagulants from tumor cell can increase the risk for VTE, and it would be more necessary to receive some antithrombotic drugs for VTE prophylaxis and prognostic improvement in patients having NSCLC with LAC-positive, which would be the most important to prevent patients from thrombotic complications for patients having lung cancer with positive LAC. This evidence concerns the gene LCT and neoplasm.